Dear E,

Artificial intelligence (AI) and machine learning (ML) are poised to make a significant impact on the life sciences industry. Pharma and biotech companies have started to implement these innovative technologies across various parts of the business to see where operations can be optimized and further drive efficiencies. However, without formulating the right questions and gathering the right data, these tools can’t realize their fullest potential.

The 4th FierceBiotech Drug Development Forum highlights how companies are leveraging AI and ML to revolutionize the drug discovery process and drive innovation across organizations to unlock new sources of economic value.

Featured Sessions

Case Study: Key Considerations When Evaluating AI Capabilities and Non-Molecule Driven Targets for Acquisition

James Robinson President and Chief Operating Officer, PARAGON BIOSCIENCES

Leverage Digital Technologies and Advanced Analytics to Unlock New Sources of Economic Value

Laurent Audoly, Ph.D., Chief Executive Officer, KYMERA THERAPEUTICS
Charles Wolfus, J.D., Vice President, Technology and Digital Health, ALECTOR

Explore How AI and Machine Learning Can Be the Backbone to Building a Hypothesis for Drug Discovery

Roman Yelensky, Ph.D., Executive Vice President and Chief Technology Officer, GRITSTONE ONCOLOGY
Ron Alfa, Ph.D., M.D., Vice President of Translational Research, RECURSION PHARMACEUTICALS
Dr. Josep Bassaganya-Riera, Chairman and CEO, LANDOS BIOPHARMA
Pat Walters, Ph.D., Senior Vice President, Computation, RELAY THERAPEUTICS
Gregory Ryslik, Ph.D., FCAS, MAAA, Chief Data Officer, CELSIUS THERAPEUTICS

Join your peers in Boston and register before September 13 to save! Please call 866-207-6528 or click here to learn more about our group rates.

Enter Priority Code 794219EM6 when signing up and mention FIERCE100.

My team and I look forward to meeting you in October!

Best regards,

Zohaib Sheikh
Senior Conference Director
ExL Events, a division of Questex, LLC
zsheikh@questex.com